Melanin-targeted [18F]-PFPN PET imaging may shed light for clear cell sarcoma

被引:3
|
作者
Zhang, Xiao [1 ,2 ,3 ]
Kang, Fei [4 ]
Zheng, Huaiyuan [5 ]
Gai, Yongkang [1 ,2 ]
Wang, Jing [4 ]
Lan, Xiaoli [1 ,2 ,3 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Nucl Med, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China
[2] Hubei Key Lab Mol Imaging, Wuhan 430022, Peoples R China
[3] Minist Educ, Key Lab Biol Targeted Therapy, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China
[4] Fourth Mil Med Univ, Xijing Hosp, Dept Nucl Med, 127 West Changle Rd, Xian, Peoples R China
[5] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Hand Surg, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China
基金
中国国家自然科学基金;
关键词
F-18]-PFPN; Melanin; F-18]-FDG; PET/MRI; Clear cell sarcoma;
D O I
10.1007/s00259-023-06439-2
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose Intracytoplasmic melanin pigment is a characteristic of clear cell sarcoma (CCS), which is a particularly deadly type of soft-tissue sarcoma. [F-18]-N-(2-(diethylamino)ethyl)-5-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)picolinamide ([F-18]-PFPN) is a positron emission tomography (PET) probe characterized by high melanin affinity. Therefore, this study aimed to investigate the feasibility of melanin-targeted [F-18]-PFPN PET in patients with CCS.Methods This prospective single-centre study recruited patients with pathologically confirmed CCS. [F-18]-FDG PET/computed tomography and [F-18]-PFPN PET/magnetic resonance imaging scans were performed within 1 week of each other. The lesion numbers and [F-18]-FDG and [F-18]-PFPN PET parameters (maximum standardized uptake value [SUVmax], mean standardized uptake value [SUVmean], metabolic/melanotic tumour volume [MTV/MLTV], and total lesion glycolysis/melanin [TLG/TLM]) were collected.Results Three patients with CCS were recruited and received PET imaging. A total of 56 lesions were detected on [F-18]-PFPN PET, including primary tumour and distant metastases. Identical lesions were not detected on [F-18]-PFPN and [F-18]-FDG PET. Twelve lesions (12/39, 30.77%) on [F-18]-FDG imaging were missed on [F-18]-PFPN, and 20 lesions (20/47, 42.55%) on [F-18]-PFPN imaging were missed on [F-18]-FDG. In quantitative analysis, the [F-18]-FDG SUVmean (4.60 +/- 3.24) was higher than the [F-18]-PFPN SUVmean (3.0 +/- 2.63) in all lesions (P=0.01). No significant correlations were found between the SUVmax, SUVmean, MLTV/MTV, and TLM/TLG values of [F-18]-PFPN and [F-18]-FDG (P>0.05).Conclusion Melanin-targeted [F-18]-PFPN PET imaging is feasible for the diagnosis of CCS. Different imaging features were displayed on [F-18]-PFPN and [F-18]-FDG PET imaging, demonstrating the complementary role of the tracers. Combined use of the two imaging modalities would be preferred in patients with CCS.
引用
收藏
页码:196 / 201
页数:6
相关论文
共 50 条
  • [11] Biodistribution, Radiation Dosimetry, and Clinical Application of a Melanin-Targeted PET Probe, 18F-P3BZA, in Patients
    Ma, Xiaowei
    Wang, Shengjun
    Wang, Shuailiang
    Liu, Daliang
    Zhao, Xiaohu
    Chen, Hao
    Kang, Fei
    Yang, Weidong
    Wang, Jing
    Cheng, Zhen
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (01) : 16 - 22
  • [12] Preparation and characterization of a novel Al18F-NOTA-BZA conjugate for melanin-targeted imaging of malignant melanoma
    Chang, Chih-Chao
    Chang, Chih-Hsien
    Lo, Yi-Hsuan
    Lin, Ming-Hsien
    Shen, Chih-Chieh
    Liu, Ren-Shyan
    Wang, Hsin-Ell
    Chen, Chuan-Lin
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (16) : 4133 - 4139
  • [13] Biodistribution, pharmacokinetics and PET Imaging of [18F]FMISO, [18F] FDG and [18F]FAc in a sarcoma- and inflammation-bearing mouse model
    Liu, Ren-Shyan
    Chou, Ta-Kai
    Chang, Chih-Hsien
    Wu, Chun-Yi
    Chang, Chi-Wei
    Chang, Tsui-Jung
    Wang, Shih-Jen
    Lin, Wuu-Jyh
    Wang, Hsin-Ell
    NUCLEAR MEDICINE AND BIOLOGY, 2009, 36 (03) : 305 - 312
  • [14] [18F]MEL050 as a melanin-targeted PET tracer: Fully automated radiosynthesis and comparison to 18F-FDG for the detection of pigmented melanoma in mice primary subcutaneous tumors and pulmonary metastases
    Rizzo-Padoin, Nathalie
    Chaussard, Michael
    Vignal, Nicolas
    Kotula, Ewa
    Tsoupko-Sitnikov, Vadim
    Vaz, Sofia
    Hontonnou, Fortune
    Liu, Wang-Qing
    Poyet, Jean-Luc
    Vidal, Michel
    Merlet, Pascal
    Hosten, Benoit
    Sarda-Mantel, Laure
    NUCLEAR MEDICINE AND BIOLOGY, 2016, 43 (12) : 773 - 780
  • [15] 18F-FDG PET/CT in a Case of Clear Cell Sarcoma of the Kidney
    Jin, Hongfu
    Yin, Yafu
    Wang, Hui
    Cheng, Weiwei
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (05) : 468 - 469
  • [16] Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT
    Rowe, Steven P.
    Gorin, Michael A.
    Hammers, Hans J.
    Javadi, M. Som
    Hawasli, Hazem
    Szabo, Zsolt
    Cho, Steve Y.
    Pomper, Martin G.
    Allaf, Mohamad E.
    ANNALS OF NUCLEAR MEDICINE, 2015, 29 (10) : 877 - 882
  • [17] Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT
    Steven P. Rowe
    Michael A. Gorin
    Hans J. Hammers
    M. Som Javadi
    Hazem Hawasli
    Zsolt Szabo
    Steve Y. Cho
    Martin G. Pomper
    Mohamad E. Allaf
    Annals of Nuclear Medicine, 2015, 29 : 877 - 882
  • [18] First-in-humans application of 18F-DMPY2: a prospective melanin-targeted PET probe in malignant melanoma patients.
    Yang, Yi
    Hu, Shuo
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [19] [18F]RPS-547: Improving the pharmacokinetics of [18F]RPS-544 for CXCR4 targeted PET Imaging
    Amor-Coarasa, A.
    Kelly, J. M.
    Nikolopoulou, A.
    Singh, P. K.
    Williams, C.
    Vedvyas, Y.
    Jin, M. M.
    Warren, J. D.
    Babich, J. W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S649 - S650
  • [20] 18F-FDG PET/CT in Clear Cell Sarcoma With Multiple Bone Metastases
    Long, Tingting
    Hu, Shuo
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (06) : 566 - 568